Marker Therapeutics, Inc.
6 clinical trials · Sponsor
◉ Watch Marker Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer (NCT06549751) | Marker Therapeutics, Inc. | 2026-07-16 |
| Safety of MT-401-OTS in Patients With Relapsed AML or MDS (NCT06552416) | Marker Therapeutics, Inc. | 2025-06-16 |
| Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma (NCT05798897) | Marker Therapeutics, Inc. | 2023-01-02 |
| Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant (NCT04511130) | Marker Therapeutics, Inc. | 2020-10-14 |
Track Marker Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.